Cargando…

A miR‐15a related polymorphism affects NSCLC prognosis via altering ERCC1 repair to platinum‐based chemotherapy

Platinum‐based chemotherapy is regarded as a preferential curative‐intent option for non‐small cell lung cancer (NSCLC), while the acquired drug resistance has become a major obstacle that limits its clinical application. Since the repair efficiency of tumour cells to platinum‐DNA adducts plays a cr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xue, Ping, Zhang, Guopei, Zhang, Hongchao, Cui, Su, Zhang, Liang, Yu, Tao, Xiao, Mingyang, Li, Liuli, Lu, Xiaobo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9639052/ https://www.ncbi.nlm.nih.gov/pubmed/36181289 http://dx.doi.org/10.1111/jcmm.17566

Ejemplares similares

AC138128.1 an Intronic lncRNA originating from ERCC1 Implies a Potential Application in Lung Cancer Treatment
por: Xiao, Mingyang, et al.
Publicado: (2019)

Rs3212986 polymorphism, a possible biomarker to predict smoking‐related lung cancer, alters DNA repair capacity via regulating ERCC1 expression
por: Yu, Tao, et al.
Publicado: (2018)

Association between the ERCC1 polymorphism and platinum-based chemotherapy effectiveness in ovarian cancer: a meta-analysis
por: Tang, Ning, et al.
Publicado: (2017)

Polymorphisms in TS, MTHFR and ERCC1 genes as predictive markers in first-line platinum and pemetrexed therapy in NSCLC patients
por: Krawczyk, Paweł, et al.
Publicado: (2014)

The expression of ERCC1 and BRCA1 predicts prognosis of platinum-based chemotherapy in urothelial cancer
por: Song, Wenhui, et al.
Publicado: (2016)

The polymorphisms of miRNA‐binding site in MLH3 and ERCC1 were linked to the risk of colorectal cancer in a case–control study
por: Zhang, Qianye, et al.
Publicado: (2018)

ERCC1 polymorphisms as prognostic markers in T4 breast cancer patients treated with platinum-based chemotherapy
por: Palomba, Grazia, et al.
Publicado: (2014)

Prevalence of CTR1 and ERCC1 Polymorphisms and Response of Biliary Tract Cancer to Gemcitabine-Platinum Chemotherapy
por: Pongmaneratanakul, Skolchart, et al.
Publicado: (2017)

Effect of ERCC1 polymorphisms on the response to platinum-based chemotherapy: A systematic review and meta-analysis based on Asian population
por: Wu, Xiaoqing, et al.
Publicado: (2023)

Chinese C allele carriers of the ERCC5 rs1047768 polymorphism are more sensitive to platinum-based chemotherapy: a meta-analysis
por: Xu, Meizhen, et al.
Publicado: (2017)

A common polymorphism in the 5′ UTR of ERCC5 creates an upstream ORF that confers resistance to platinum-based chemotherapy
por: Somers, Joanna, et al.
Publicado: (2015)

Study of the Relationship between ERCC1 Polymorphisms and Response to Platinum-based Chemotherapy in Iranian Patients with Colorectal and Gastric Cancers
por: Abyarghamsari, Mahdiye, et al.
Publicado: (2019)

Association between common polymorphisms in ERCC gene and prognosis of osteosarcoma in patients treated with chemotherapy: a meta-analysis
por: Li, Chunpu, et al.
Publicado: (2018)

Meta-analysis showing that ERCC1 polymorphism is predictive of osteosarcoma prognosis
por: Liu, Xueyong, et al.
Publicado: (2017)

Single-arm, open label prospective trial to assess prediction of the role of ERCC1/XPF complex in the response of advanced NSCLC patients to platinum-based chemotherapy
por: Ganzinelli, M., et al.
Publicado: (2021)

ERCC1_202 Is A Prognostic Biomarker in Advanced Stage Non-Small Cell Lung Cancer Patients Treated with Platinum-Based Chemotherapy
por: Wang, Xiyong, et al.
Publicado: (2017)

OPN Polymorphism Is Related to the Chemotherapy Response and Prognosis in Advanced NSCLC
por: Hao, Yanzhang, et al.
Publicado: (2014)

Polymorphisms of CCNB1 Associated With the Clinical Outcomes of Platinum-Based Chemotherapy in Chinese NSCLC Patients
por: Liu, Di, et al.
Publicado: (2017)

Influence of Programmed Death Ligand-1-Gene Polymorphism rs822336 on the Prognosis and Safety of Postoperative Patients with NSCLC Who Received Platinum-Based Adjuvant Chemotherapy
por: Zhao, Ming, et al.
Publicado: (2020)

Genetic polymorphisms in ERCC1 and ERCC2 genes are associated with response to chemotherapy in osteosarcoma patients among Chinese population: a meta-analysis
por: Zhang, Haiguang, et al.
Publicado: (2017)

ERCC1, XRCC1, and GSTP1 Polymorphisms and Treatment Outcomes of Advanced Epithelial Ovarian Cancer Patients Treated with Platinum-based Chemotherapy
por: Liblab, Salisa, et al.
Publicado: (2020)

ERCC1 Expression in Metastatic Triple Negative Breast Cancer Patients Treated with Platinum-Based Chemotherapy
por: Baiomy, Mohamed Ali EL, et al.
Publicado: (2017)

Association of ERCC1 and ERCC2 polymorphisms with colorectal cancer risk in a Chinese population
por: Ni, Min, et al.
Publicado: (2014)

BMP-4 Genetic Variants and Protein Expression Are Associated with Platinum-Based Chemotherapy Response and Prognosis in NSCLC
por: Xian, Sun, et al.
Publicado: (2014)

Genetic polymorphisms of ERCC-1 and ERCC-2 are not prognostic markers in osteosarcoma patients with chemotherapy: A meta-analysis in Chinese population
por: Liu, Dabiao, et al.
Publicado: (2018)

A Significant Statistical Advancement on the Predictive Values of ERCC1 Polymorphisms for Clinical Outcomes of Platinum-Based Chemotherapy in Non-Small Cell Lung Cancer: An Updated Meta-Analysis
por: Han, Yali, et al.
Publicado: (2016)

Effect of the ERCC1 (C118T) Polymorphism on Treatment Response in Advanced Non-Small Cell Lung Cancer Patients Undergoing Platinum-Based Chemotherapy
por: Kaewbubpa, Walennee, et al.
Publicado: (2016)

Pharmacogenetic Association between XRCC1 Polymorphisms and Response to Platinum-Based Chemotherapy in Asian Patients with NSCLC: A Meta-Analysis
por: Zhang, Ningning, et al.
Publicado: (2020)

ERCC1 rs11615 polymorphism and chemosensitivity to platinum drugs in patients with ovarian cancer: a systematic review and meta-analysis
por: Zhang, Yuqiang, et al.
Publicado: (2021)

Polymorphisms in ERCC2 and ERCC5 and Risk of Prostate Cancer: A Meta-Analysis and Systematic Review
por: Liu, Yi, et al.
Publicado: (2018)

Association between common polymorphisms in ERCC gene and glioma risk: A meta-analysis of 15 studies
por: Qian, Tengda, et al.
Publicado: (2017)

The role of expression and polymorphism of the BAG-1 gene in response to platinum-based chemotherapeutics in NSCLC
por: WANG, YA-DI, et al.
Publicado: (2011)

ERCC1 and the Prognosis for Patients With Colon Cancer Receiving Oxaliplatin-Based Adjuvant Chemotherapy
por: Baek, Moo-Jun
Publicado: (2015)

The Association of ERCC1 and ERCC5 Polymorphisms with Lung Cancer Risk in Han Chinese
por: Lan, Xueling, et al.
Publicado: (2022)

ERCC1/BRCA1 expression and gene polymorphisms as prognostic and predictive factors in advanced NSCLC treated with or without cisplatin
por: Tiseo, M, et al.
Publicado: (2013)

The predictive value of ERCC1 and p53 for the effect of panobinostat and cisplatin combination treatment in NSCLC
por: Cai, Yang, et al.
Publicado: (2015)

Polymorphisms in ERCC1, GSTs, TS and MTHFR predict clinical outcomes of gastric cancer patients treated with platinum/5-Fu-based chemotherapy: a systematic review
por: Wang, Zhen, et al.
Publicado: (2012)

DNA repair gene ERCC2 polymorphisms and associations with breast and ovarian cancer risk
por: Bernard-Gallon, Dominique, et al.
Publicado: (2008)

The Effects of WISP1 Polymorphisms on the Prognosis of Lung Cancer Patients with Platinum-Based Chemotherapy
por: He, Jia, et al.
Publicado: (2021)

Phase II trial of a non‐platinum triplet for patients with advanced non‐small cell lung carcinoma (NSCLC) overexpressing ERCC1 messenger RNA
por: Takemoto, Shinnosuke, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_gmub0fcbfoe99ah170egku77pm